Director/PDMR Shareholding

Summary by AI BETAClose X

Quantum Helium Limited announced that Non-Executive Director Graham Duncan purchased 39,300,000 ordinary shares at 0.039 pence per share between December 29, 2025, and January 7, 2026, increasing his beneficial interest to 100,250,617 ordinary shares, representing 0.30% of the company's total voting rights. This transaction is considered inside information under Market Abuse Regulations and is now public.

Disclaimer*

Quantum Helium Limited
08 January 2026
 

 

8 January 2026

 

Quantum Helium Limited

("Quantum" or the "Company")

 

 

Director / PDMR Shareholding

Quantum Helium Limited (AIM: QHE) announces that Non-Executive Director, Graham Duncan, has informed the Company that between 29 December 2025 and 7 January 2026, he purchased a total of 39,300,000 Ordinary Shares in the Company at a price of 0.039 pence per share.

Following these trades, Graham Duncan now has a beneficial interest in 100,250,617 Ordinary Shares, representing 0.30% of the current total voting rights of the Company.

 

Market Abuse Regulation (MAR) Disclosure

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service ('RIS'), this information is now considered to be in the public domain.

 

 

Enquiries:

Quantum Helium Limited

Carl Dumbrell

Chairman

 

NOMAD and Joint Broker

SP Angel Corporate Finance LLP

Stuart Gledhill / Richard Hail / Adam Cowl

+44 (0) 20 3470 0470

Brand Communications

Alan Green

Tel: +44 (0) 7976 431608

Joint Broker

CMC Markets UK Plc

Douglas Crippen

+44 (0) 020 3003 8632

 

Updates on the Company's activities are regularly posted on its website: www.quantum-helium.com

 

Notes to editors

Quantum (AIM: QHE) is a helium, hydrogen and hydrocarbon exploration, development, and production company with projects in the US and Australia. Quantum's strategic objectives remain consistent: to identify opportunities which will provide operating cash flow and have development upside, in conjunction with progressing exploration. The Company has several projects in the US, in addition to royalty interests in Australia.

 

 

 

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Graham Duncan

 

2.

Reason for the notification

a)

Position/status

Non-Executive Director

 

b)

Initial notification/
amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Full name of the entity

Quantum Helium Limited

b)

Legal Entity Identifier code

213800PWZID9URNNGZ54

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of Quantum Helium Ltd



AU0000XINET1

b)

Nature of the transaction

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.039p

 

39,300,000



d)

Aggregated information

-     Aggregated volume

-     Price

 

39,300,000

 

0.039p

e)

Date of the transaction

1)  29 December 2025 to 7 January 2026

 

 

 

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings